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Overexpression of Smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma
Audrey Lamora [1] [2] [3] [4] 
Introduction
Osteosarcoma is the most common primary malignant bone tumor in children and adolescents with a second peak of incidence in adults over the age of 65 (1) . Although several predisposing environmental (e.g. ionizing radiation) and genetic (e.g.TP53) factors have been identified (2) , the exact etiology of this disease remains unknown (3) . These rare tumors, believed to originate from mesenchymal cells forming the primitive bone, preferentially grow in the metaphysis of long bone (4) .
Approximately 20% of patients have lung metastasis at initial diagnosis and an additional 40% will develop metastasis during the later stages of disease. The presence of metastasis at diagnosis is the most important predictor of disease-free survival with a 5-year survival rate of only 20% for osteosarcoma patients with metastasis compared to 65% for patients with localized disease (5) . The standard treatment of osteosarcoma consists of complete surgical resection associated with neoadjuvant and adjuvant chemotherapy composed of four agents: doxorubicin, cisplatin, methotrexate or ifosfamide (6) . These combined treatment protocols have significantly improved survival of the non-metastatic patients over the past several decades (7, 8) . Unfortunately, such therapeutic strategies have a limited efficacy in the treatment of metastatic disease, and the metastatic relapse or recurrent conditions have remained unchanged over the last 3 decades (8) . Treating
The role of TGF-β in cancer is complex. During the first stages of the development of primitive tumors from epithelial origin, the TGF-β/Smad cascade acts as a tumor suppressor mainly through inhibition of cell proliferation and/or promotion of cell apoptosis (11, 12, 17) . Contrarily, during the later stages, the TGF-β cascade promotes tumor progression mainly by its ability to stimulate epithelial to mesenchymal transition, tumor invasion, metastatic dissemination and/or evasion of the immune system (12, 13, 17) . With regard to bone cancers, most studies have focused on the role of TGF-β in the development of bone metastasis. The contributions of TGF-β to breast cancer and melanoma bone metastasis have been well described (18-21). TGF-β promotes bone metastasis by its ability to promote the metastatic process by stimulating MMP-2 production and thus promoting cellular invasion of melanoma (19, 20) . It has been reported that TGF-β contributes to the establishment of a vicious cycle between epithelial tumor cells and bone cells. Briefly, the tumor cells secrete osteoclastactivating factors that promote bone degradation thus stimulating the release of factors which in turn will promote bone metastasis development (22, 23) . In this context, it has been shown that overexpression of the TGF-β inhibitor Smad7 in melanoma cells reduces the development of melanoma bone metastasis, and that the use of chemical inhibitors targeting TβRI reduces the development and progression of both, melanoma and breast cancer bone metastasis (21) . With regard to primary bone sarcomas, few studies have described the role of TGF-β on tumor development. It has been shown that the production of TGF-β1 is associated with high-grade osteosarcoma (24, 25) and that TGF-β stimulates the growth of several osteosarcoma cell lines in culture (26) suggesting that TGF-β could favor osteosarcoma development.
In this study, we particularly demonstrate that the overexpression of the inhibitory Smad, Smad7, in osteosarcoma cells and treatment of mice with a specific inhibitor of TβRI (SD-208) block the development of osteosarcoma lung metastasis.
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Author Manuscript Published OnlineFirst on August 8, 2014 ; DOI: 10.1158/1078-0432.CCR- Total RNA from tumors was extracted using the TRIzol reagent (Invitrogen Life Technologies) after mechanical grinding with Turrax (IKA, Staufen, Switzerland). qRT-PCR were performed as previously described (27) . Primer sequences are provided in Table 1 .
Transient cell transfections, reporter assays and plasmid constructs
Transient cell transfections were performed with jetPEI TM (Polyplus-transfection, Illkirch, France). The phRLMLP-Renilla luciferase expression vector was cotransfected in all experiments to monitor transfection efficiencies. Luciferase activity was determined with the Dual-Luciferase reporter assay system (Promega, Charbonnieres, France). The (CAGA) 9 -Luc construct was used as a reporter construct specific for Smad3/4-driven signaling (28). The pcDNA-Smad7 vector is a kind gift from Dr Alain Mauviel (19) .
Osteosarcoma mouse model
Four-week-old female Rj:NMRI-nude mice (Elevages Janvier, Le Genest Saint Isle, France) were 
Micro-CT analysis
Analysis of bone microarchitecture was performed as previously described (27) at different tumor volumes (250, 1000 and 2500mm 3 ). All tibiae/fibulae were scanned using the same parameters (pixel Research. size 18 µm, 50kV, 0.5-mm Al filter and 0.8 degrees per rotation step). Three-dimensional reconstructions and analysis of bone parameters were performed using the CTvol and CTan software (Skyscan).
Histologic Analysis
After sacrifice, the tibiae were conserved and fixed in 10% buffered formaldehyde, decalcified (4% EDTA, 0.2% paraformaldehyde, pH 7.4), and embedded in paraffin. 3-µm sections of tumor-bearing tibiae were cut and stained for tartrate-resistant acid phosphatase (TRAP) to analyze osteoclast activity. Lungs were fixed in 10% buffered formaldehyde and embedded in paraffin. Lung sections (3μm-thick) were mounted on glass slides and stained with hematoxylin-eosin (HE).
Immunohistochemistry of human and mice tumor samples
3-µm sections of human tumor tissues (embedded in paraffin) were cut and stained for phosphoSmad3 using rabbit polyclonal anti-phosphoSmad3 antibody (Abcam). Patient tumor clinical samples collected at Nantes University Hospital (Nantes, France) were obtained following patient informed consent and after ethical approval by the Nantes University Hospital Ethics Committee.
3-µm sections of mice tumor tissues (embedded in paraffin) were cut and stained for osterix, RANKL, osteocalcin, caspase-3, Ki-67 and CD146 using respectively rabbit polyclonal anti-osterix (Abcam), anti-RANKL (Santa Cruz Biotechnology), anti-osteocalcin (Abcam), anti-caspase-3 (Cell Signaling), anti-Ki67 (Dako), anti CD146 (Abcam) antibodies. Immunodetection was performed using DAB Substrate-Chromogen (Dako) and counterstained with hematoxylin.
Collagen degradation. The degradation of collagen was evaluated by the measure of pyridinoline excretion in mice serum using the MicroVue Serum PYD EIA kit.
Transwell
TM motility and invasion. Osteosarcoma cells (30 000 cells/well) were pre-treated with 5 ng/ml TGF-β in the presence or absence of SD-208 (10µM) for 24 h and seeded onto the upper surface of transwell inserts (Falcon, Franklin Lakes, NJ) coated with 0.1 mg/ml of growth factorreduced Matrigel TM (Biocoat, BD Biosciences, SanJose, CA) for the invasion assay, or on uncoated transwells (migration assay) and incubated at 37°C for 48 h. At the end of the incubation period, cells
Research. on the upper surface of the inserts were wiped off, and the cells on the underside of the membrane were fixed, stained with "cristal violet" and counted by bright-field microscopy in five random fields.
Gelatin zymography. Cells were cultured for 48 h without serum and their conditioned media were analyzed by gelatin zymography in 10% polyacrylamide gels containing 1 mg/ml gelatin (SigmaAldrich) as described previously (19) .
Statistical analysis
All analyses were performed using GraphPad Prism 4.0 software (GraphPad Software, La Jolla, CA, USA). Results of in vitro experiments were analyzed with the unpaired t-test and are given as means ± SD. For in vivo experiments, results from groups overexpressing Smad7 were compared with control groups (parental and mock) and results from mice treated with SD-208 were compared with untreated mice using the unpaired t-test and are given as means ± SEM. Results of animal survival were analyzed using the log-rank test. Results with p<0.05 were considered significant.
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Results
High levels of TGF-β1 and TGF-β2 are measured in serum of osteosarcoma patients TGF-β1, TGF-β2 and TGF-β3 levels were measured in the serum of forty osteosarcoma patients and compared with twenty age-matched healthy volunteers. As shown in Figure 1A (upper panels), TGF-β1 (left panel) and TGF-β2 (right panel) concentrations measured in the serum were significantly higher in the serum of osteosarcoma patients compared to healthy volunteers (p<0.01 and p<0.0001 for TGF-β1 and TGF-β2 respectively). Note that the TGF-β3 serum levels were very low, under the (Fig. 1C, left panel) , and to stimulate the expression of CTGF, PAI-1 and COL1A1 (Fig. 1D, upper panels) . Similar results were obtained with the SaOS2 cell line (Supplementary Fig. S1 ). Note that the overexpression of Smad7 partially inhibits a BMP-specific target gene such as ID1 (Supplementary Fig. S1C ) but not the ability of TGF-β to induce the activation of MAPKinases such as ERK 1/2 ( Supplementary Fig. S1D ). To specifically target the TGF-β cascade, we secondly studied the effect of a TβRI inhibitor, the chemical Figure 1D , lower panels) in HOS cells and in SaOS2 cells (Supplementary Fig. S1 ). Note that in contrast to Smad7 overexpression, the SD-208 inhibitor is able to block the ability of TGF-β to activate the phosphorylation of ERK 1/2 (Supplementary Figure S1D, Consequently, Smad7 overexpression resulted in an increased animal survival in both models ( Fig These results demonstrate that overexpression of Smad7 reduced in vivo tumor growth and suggest that this effect is not due to a direct effect of Smad7 on osteosarcoma cell proliferation.
on We next determined whether this increase in total bone volume was due either to direct new bone formation (ectopic bone) and/or to an inhibition of bone resorption. As shown in Figure 3B (Fig. 3D right panel) .
These results demonstrate that in contrast with SD-208 mice treatment, overexpression of Smad7 in osteosarcoma cells both decreased tumor-associated bone osteolysis and promoted tumor-associated bone formation.
Overexpression of Smad7 in HOS and SaOS2 osteosarcoma cells reduces osteoclast activity
The activity of osteoclasts and osteoblasts, two cell lineages implicated in bone remodeling, was then assessed during the early stages of tumor growth (tumor size ≤ 250 mm 3 expressed significantly lower mRNA levels of RANKL (Fig. 4B, lower panel) . Finally, the degradation of collagen evaluated by the measure of pyridinoline excretion in mice serum is decreased when Smad7 is overexpressed in osteosarcoma cells (Fig. 4C ).
In addition to RANKL, the expression of other TGF-β target genes implicated in bone remodeling (18,20,21) such as interleukin-11 (IL-11) and osteopontin (OPN) is decreased when Smad7 is overexpressed. As shown in Figure 4D , q-PCR analysis indicated that the IL-11 and OPN expressions were increased in response to TGF-β and that Smad7 overexpression prevented such induction ( Fig   4D, left panel) . HOS-S7 bone tumors expressed significantly lower levels of IL-11 and osteopontin
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These results demonstrate that Smad7 overexpression decreases osteoclast activity and thus bone osteolysis at least in part via the modulation of osteolytic genes such as RANKL.
Overexpression of Smad7 in HOS and SaOS2 osteosarcoma cells or treatment of mice with SD-208 inhibit dissemination of pulmonary metastasis
To evaluate the effect of Smad7 on pulmonary metastasis development (Fig. 5A) , the lungs of mice were removed when primary tumor volumes reached 2500 mm 3 . As shown in Figure 5B Fig. S2C ). qRT-PCR analysis indicated a reduction of TGF-β-induced MMP-2 mRNA levels in Smad7 transfected-or SD-208-treated cells (Fig. 6D upper panels) . MMP-2 mRNA steadystate levels were increased by approximately 5-fold in parental and mock-transfected HOS cells, but only by 2-fold in HOS-S7 cells after treatment of osteosarcoma cells with TGF-β (5 ng/ml) for 24h.
Similar results were obtained when Smad7 was overexpressed in SaOS2 cells (Supplementary Fig.   S2D ) or when osteosarcoma cells were treated with SD-208 (Fig. 6D , right panel and Supplementary   Fig. S2D right panel) . In addition, both HOS-S7 bone tumors and HOS cells from mice treated with SD-208 expressed significantly lower levels of MMP-2 (Fig. 6D, lower panel) .
These results demonstrated that overexpression of Smad7 in osteosarcoma cells or treatment of mice with SD-208 blocks the formation of lung metastasis.
Discussion
Increased TGF-β1 mRNA and/or protein expression has been correlated with a wide range of cancers such as colorectal cancer, gastric carcinoma, or prostate cancer (31-34). This increase in serum TGF-β1 production and/or TGF-β1 staining in tumor cells has been associated with disease progression to metastasis in these carcinomas (31). Here, we demonstrated that high concentrations of TGF-β1 and TGF-β2 measured in serum of patients is associated with osteosarcoma disease. In addition, using clinical samples, we demonstrated that the Smad3 cascade is activated in osteosarcoma cells particularly in high-risk patients when lung metastasis are detected at diagnosis. Previous studies have reported that high levels of TGF-β1 mRNA in tumor cells are associated with high-grade osteosarcoma, which shows an aggressive behavior and frequently metastasizes to lung or other sites (24) . These observations together with our results suggest that high levels of TGF-β1 in serum could be associated with a poor prognosis in osteosarcoma. 
CCR-13-3191
In this context, since osteosarcoma-associated alterations of bone remodeling play a central role in the development and progression of osteosarcoma, we studied the effect of Smad7 on bone remodeling. We clearly demonstrated that Smad7 overexpression in osteosarcoma cells slows bone destruction associated with the tumor growth. In this context, we demonstrated that this process was mainly associated with a reduction of trabecular bone destruction during the early stages of tumor growth (when tumor volumes were below 250 mm 3 ) and with an increase of ectopic bone formation during the late stages of tumor growth (when tumor volumes were greater than 1000 mm 3 ). The presence of a "vicious cycle" established between tumor proliferation and paratumor osteolysis plays a crucial role in the development of primary bone tumors (37) . Cancer cells produce soluble factors that activate directly or indirectly via osteoblasts, the osteoclast differentiation and maturation (38, 39) . In turn, during bone degradation, osteoclasts allow the release of growth factors stored in the mineralized bone matrix that are able to stimulate tumor growth. In this context, we demonstrated that the resulting increase in bone volume observed after Smad7 overexpression in osteosarcoma cells is due in large part to the inhibition of osteoclast activity. The decrease of TRAP activity at the growth plate level, which is not in direct contact with the tumor, suggests that Smad7 overexpression affects the ability of the tumor cells to produce a soluble factor able to regulate osteoclast activity. Here, we clearly demonstrated that Smad7 overexpression in osteosarcoma cells inhibits their ability to produce RANKL or IL-11, two cytokines which play a central role in bone osteolysis process (40) . Together, these results suggest that Smad7 slows the tumor growth by acting at least at the tumor environment level, by inhibiting the tumor associated bone osteolysis.
Surprisingly, we did not observe a significant effect of SD-208 on tumor growth. Several hypotheses can be proposed to explain this difference between Smad7 and SD-208 effects on tumor growth.
Firstly, we cannot rule out that Smad7 may also exert some of its action independently from its role as a TGF-β signaling inhibitor. Indeed, Smad7 is able to inhibit other signaling pathways such as the cascade of Bone Morphogenetic Protein family members (BMPs), highly involved in bone formation (41) . This hypothesis seems unlikely since the BMPs are known to promote bone formation. Thus, we
can hypothesize that BMP inhibitors should promote bone degradation by inhibiting the bone formation in contrast to the results observed by over-expression of Smad7. Secondly, Smad7 might have several distinct functions in cellular signaling (12) . For example it has been shown that Smad7 overexpression is able to potentiate apoptosis in prostate carcinoma and in PC-3U cells (12) . In
Research. Although we have not observed an effect of Smad7 on the proliferation and apoptosis of osteosarcoma cells, or on the ability of TGF-β to stimulate the MAPK pathway, we cannot rule out this hypothesis. Thirdly, the inefficiency of SD-208 on tumor growth can be explained by its inability to reduce the tumor associated bone osteolysis. Indeed, although a systemic treatment of mice with SD-208 promotes bone formation in absence of tumor as previously described (30), this systemic treatment does not seem to reduce the tumor associated bone osteolysis in contrast with the overexpression of Smad7 effect in osteosarcoma cells. In addition, the HOS mice model used in these experiments is a high aggressive model with a fast bone degradation associated with tumor growth.
The effectiveness of a local mice treatment with SD-208 directly into the tumor cells using a less aggressive model should be tested.
Finally, we showed that both Smad7 overexpression and SD-208 strongly affect the ability of the primary bone tumor to develop lung metastasis demonstrating the crucial role of TGF-β/Smad signaling pathway in the metastatic process of osteosarcoma. During the last decades, the role of TGF-β in the metastatic process of carcinomas has been widely described. A major step in this process is the ability of TGF-β to stimulate epithelial-to-mesenchymal transition and thus the ability of tumor cells to invade adjacent tissues (17). In the context of osteosarcoma cells which are from mesenchymal origin, we specifically demonstrated that Smad7 overexpression and SD-208 block the ability of TGF-β to stimulate osteosarcoma migration and invasion. In this context, we clearly demonstrated that Smad7 and SD-208 are able to block TGF-β-induced MMP-2 activity, mainly involved in the invasion process such as described in the context of melanoma bone metastasis (19, 20) . Another major step in the metastatic process is the ability of TGF-β to stimulate tumor 
